Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022)
Soleno Intends to Submit a New Drug Application for DCCR in PWS Mid-Year 2024
Company to Host Conference Call and Webcast Today at 9:00 AM ET
Conference Call and Webcast Details
Soleno will host a conference call and webcast to discuss these results today, September 26, 2023 at 9:00 AM ET. Details can be found below:
Title: | Randomized Withdrawal Period of Study C602 Top-line Results |
Date: | Tuesday, September 26, 2023 |
Time: | 9:00 AM ET |
Conference Call Details: | Toll-free: 1-877-423-9813 |
Call me™ Feature (avoid waiting for operator): | |
Webcast: |
A replay of the call will be available following the call on the Investors section of the Soleno website.
https://finance.yahoo.com/news/soleno-therapeutics-announces-positive-statistically-113000169.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.